Refine your search
2,130 results found
Lexology PRO | Asia-Pacific, Australia, China, etc. | 16 Jun 2022
Key patent litigation so far in 2022
Litigation on SEPs, pharmaceutical patent infringement, and inter partes review has dominated patent litigation in the first half of 2022.
Lexology PRO | Asia-Pacific, Canada, European Union, etc. | 15 Jun 2022
Trademark and copyright: key updates for in-house teams (June 2022)
Hermès survives a motion to dismiss in its NFT trademark infringement claim, Russia introduces new IP payments procedures, and the copyright claims board begins accepting cases – plus other key updates.
Lexology PRO | Asia-Pacific, Australia, China, etc. | 3 Mar 2022
Patents: key updates and developments for in-house teams (27 Jan – 2 Mar)
The US Federal Circuit invalidates Caltech’s US$1.1 billion award against Apple, the EU files a case against China before the WTO, and the UK launches a new IP infringement strategy – plus other key updates.
Duane Morris LLP | USA | 17 Feb 2022
PTAB Confirms Petitioners Must Make Two Distinct Showings to Prove a Primary Patent Reference’s Entitlement to a Provisional Application’s Filing Date
In a January 27, 2022 non-precedential decision in IPR2021-01328, the Patent Trial and Appeal Board (“PTAB”) denied institution of an inter partes…
McDermott Will & Emery | USA | 10 Feb 2022
IPR Petition Cannot Be Based on Applicant Admitted Prior Art
Addressing the type of prior art that may form the basis of an inter partes review (IPR) proceeding, the US Court of Appeals for the Federal Circuit…
Lexology PRO | Asia-Pacific, China, European Union, etc. | 28 Jan 2022
Intellectual property: key patent risks and updates (8 – 26 Jan)
The Unified Patent Court enters its final preparatory stage, India extends IP deadlines in light of COVID-19, and the US Supreme Court denies a petition from Apple – plus other key updates.
McDermott Will & Emery | USA | 16 Dec 2021
Shots Fired: Challenger Must Have Requisite Standing Before Appealing Unfavorable IPR Decisions
The US Court of Appeals for the Federal Circuit found, in the context of an appeal from an inter partes review (IPR) decision, that the Appellant had…
McDermott Will & Emery | USA | 21 Oct 2021
NDA Forum Selection Clause Doesn’t Bar IPR in Response to Subsequent Infringement Suit
The US Court of Appeals for the Federal Circuit affirmed the denial of a preliminary injunction that would have forced the accused infringer to seek…
McDermott Will & Emery | USA | 16 Sep 2021
Federal Circuit: Contractual Arbitration Agreements Don’t Bind PTAB Institution Decisions
The US Court of Appeals for the Federal Circuit issued an order declining to intervene in inter partes review (IPR) institution decisions by the…
Proskauer Rose LLP | USA | 13 May 2021
When Is Less Really More for a Patent Licensee?
The development timeline for small-molecule drugs and biologics is lengthy, estimated to take between 10 and 15 years. As a result, pharmaceutical…
